Glycopeptide phosphonate derivatives
View Patent ↗Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.
1. A method of treating a staphylococcal infection in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a compound of the formula:
or a pharmaceutically-acceptable salt thereof.
2. The method of claim 1 , wherein the staphylococcal infection is caused by Staphylococcus aureus.
3. The method of claim 1 , wherein the staphylococcal infection is caused by Staphylococcus epidermidis.
4. The method of claim 1 , wherein the staphylococcal infection is caused by methicillin-resistant Staphylococcus aureus.
5. The method of claim 1 , wherein the staphylococcal infection is caused by methicillin-resistant Staphylococcus epidermidis.
6. The method of claim 1 , wherein the compound is administered intravenously.
7. The method of claim 1 , wherein the pharmaceutically-acceptable salt is a hydrochloride salt.
8. A method of treating a staphylococcal infection in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the formula:
or a pharmaceutically-acceptable salt thereof.
9. The method of claim 8 , wherein the pharmaceutical composition further comprises a cyclodextrin.
10. The process of claim 9 , wherein the cyclodextrin is hydroxypropyl-β-cyclodextrin.
11. The process of claim 9 , wherein the cyclodextrin is sulfobutyl ether β-cyclodextrin.
12. The method of claim 8 , wherein the staphylococcal infection is caused by Staphylococcus aureus.
13. The method of claim 8 , wherein the staphylococcal infection is caused by Staphylococcus epidermidis.
14. The method of claim 8 , wherein the staphylococcal infection is caused by methicillin-resistant Staphylococcus aureus.
15. The method of claim 8 , wherein the staphylococcal infection is caused by methicillin-resistant Staphylococcus epidermidis.
16. The method of claim 8 , wherein the pharmaceutical composition is administered intravenously.
17. The method of claim 1 , wherein the pharmaceutically-acceptable salt is a hydrochloride salt.
18. A method of treating a staphylococcal infection in a mammal where the infection is caused by methicillin-resistant Staphylococcus aureus, the method comprising administering a therapeutically effective amount of a composition comprising:
(A) a compound of the formula:
or a hydrochloride salt thereof; and
(b) hydroxypropyl-β-cyclodextrin.